A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A new analysis from the US-based Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, published in Neurology, examines how antiseizure medications (ASMs) were adjusted during pregnancy and early postpartum...
A new analysis from the US-based Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, published in Neurology, examines how antiseizure medications (ASMs) were adjusted during pregnancy and early postpartum...
A new clinical practice guideline from the American Academy of Neurology (AAN), published in Neurology, provides comprehensive recommendations for diagnosing and managing functional seizures.
A new clinical practice guideline from the American Academy of Neurology (AAN), published in Neurology, provides comprehensive recommendations for diagnosing and managing functional seizures.
More than two-thirds of patients with treatment-resistant focal epilepsy experienced a significant reduction of seizures over up to 3 years of follow-up, according to a study published in JAMA Neurology.
More than two-thirds of patients with treatment-resistant focal epilepsy experienced a significant reduction of seizures over up to 3 years of follow-up, according to a study published in JAMA Neurology.
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology.
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology.
Epilepsy diagnoses and the use of antiseizure medications were significantly higher among patients with frontotemporal dementia (FTD) compared with patients with Alzheimer disease (AD) and healthy controls in a case-control study.
Epilepsy diagnoses and the use of antiseizure medications were significantly higher among patients with frontotemporal dementia (FTD) compared with patients with Alzheimer disease (AD) and healthy controls in a case-control study.
Nearly half of real-world patients with drug-resistant epilepsy who received adjunctive cenobamate through an early access program experienced a 50% reduction in seizure frequency, according to recent findings.
Nearly half of real-world patients with drug-resistant epilepsy who received adjunctive cenobamate through an early access program experienced a 50% reduction in seizure frequency, according to recent findings.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A new analysis from the US-based Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, published in Neurology, examines how antiseizure medications (ASMs) were adjusted during pregnancy and early postpartum...
A new analysis from the US-based Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, published in Neurology, examines how antiseizure medications (ASMs) were adjusted during pregnancy and early postpartum...
A new clinical practice guideline from the American Academy of Neurology (AAN), published in Neurology, provides comprehensive recommendations for diagnosing and managing functional seizures.
A new clinical practice guideline from the American Academy of Neurology (AAN), published in Neurology, provides comprehensive recommendations for diagnosing and managing functional seizures.
More than two-thirds of patients with treatment-resistant focal epilepsy experienced a significant reduction of seizures over up to 3 years of follow-up, according to a study published in JAMA Neurology.
More than two-thirds of patients with treatment-resistant focal epilepsy experienced a significant reduction of seizures over up to 3 years of follow-up, according to a study published in JAMA Neurology.
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology.
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology.
Epilepsy diagnoses and the use of antiseizure medications were significantly higher among patients with frontotemporal dementia (FTD) compared with patients with Alzheimer disease (AD) and healthy controls in a case-control study.
Epilepsy diagnoses and the use of antiseizure medications were significantly higher among patients with frontotemporal dementia (FTD) compared with patients with Alzheimer disease (AD) and healthy controls in a case-control study.
Nearly half of real-world patients with drug-resistant epilepsy who received adjunctive cenobamate through an early access program experienced a 50% reduction in seizure frequency, according to recent findings.
Nearly half of real-world patients with drug-resistant epilepsy who received adjunctive cenobamate through an early access program experienced a 50% reduction in seizure frequency, according to recent findings.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine.
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine.
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
